Scope
Reference
C414011
Description
NHS Branded Medicines Tranche B - Lot 1 - London & South of England - CM/PHR/25/5731
Period of Framework Agreement: 1 September 2026 to 31 August 2028 with an option or option(s) to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
Lot 2 - Ustekinumab for North of England and Midlands & East, period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.
Commercial tool
Establishes a framework
Total value (estimated)
- £592,363,416 excluding VAT
- £710,836,100 including VAT
Above the relevant threshold
Main procurement category
Goods
CPV classifications
- 33600000 - Pharmaceutical products
Contract locations
- UKD - North West (England)
- UKJ - South East (England)
- UKK - South West (England)
- UKI - London
- UKF - East Midlands (England)
- UKG - West Midlands (England)
- UKC - North East (England)
Not the same for all lots
Contract dates and options are shown in Lot sections, because they are not the same for all lots.
Lot 1. Lot 1 - Tranche B for London & South of England
Description
NHS Branded Medicines - Tranche B for London & South of England
Lot value (estimated)
- £541,494,660 excluding VAT
- £649,793,592 including VAT
Framework lot values may be shared with other lots
Contract dates (estimated)
- 1 September 2026 to 31 August 2028
- Possible extension to 31 August 2030
- 4 years
Description of possible extension:
With an option or option(s) to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
Options
The right to additional purchases while the contract is valid.
With an option or option(s) to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
Same for all lots
CPV classifications and contract locations are shown in the Scope section, because they are the same for all lots.
Lot 2. Lot 2 - Ustekinumab for North of England and Midlands & East
Description
NHS Branded Medicines - Ustekinumab for North of England and Midlands & East
Lot value (estimated)
- £50,868,757 excluding VAT
- £61,042,508.40 including VAT
Framework lot values may be shared with other lots
Contract dates (estimated)
- 1 September 2026 to 31 August 2027
- Possible extension to 31 August 2028
- 2 years
Description of possible extension:
With an option or option(s) to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.
Options
The right to additional purchases while the contract is valid.
With an option or option(s) to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.
Same for all lots
CPV classifications and contract locations are shown in the Scope section, because they are the same for all lots.
Framework
Maximum number of suppliers
Unlimited
Maximum percentage fee charged to suppliers
0%
Framework operation description
Please refer to the ITO Documents for the Operation Description
Award method when using the framework
With competition
Contracting authorities that may use the framework
Please refer to Document No. 09 of the ITO Documents for the list of Participating Authorities/Pharmacy Purchasing Points
Participation
Particular suitability
Lot 1. Lot 1 - Tranche B for London & South of England
Lot 2. Lot 2 - Ustekinumab for North of England and Midlands & East
Small and medium-sized enterprises (SME)
Submission
Enquiry deadline
19 March 2026, 5:00pm
Tender submission deadline
26 March 2026, 1:00pm
Submission address and any special instructions
The procurement documents are available for unrestricted and full direct access, free of charge at https://health-family.force.com/s/Welcome
Additional info obtained from the abovementioned address. Tenders must be submitted to the abovementioned address
Tenders may be submitted electronically
Yes
Languages that may be used for submission
English
Award decision date (estimated)
29 May 2026
Award criteria
| Name | Description | Type |
|---|---|---|
| Price is not the only award criterion | Price is not the only award criterion and all criteria are stated only in the procurement documents |
Price |
Weighting description
Price is not the only award criterion and all criteria are stated only in the procurement documents
Other information
Applicable trade agreements
- Government Procurement Agreement (GPA)
Conflicts assessment prepared/revised
Yes
Procedure
Procedure type
Open procedure
Documents
Associated tender documents
Document No. 01 - Invitation to offer covering letter.docx
Document No. 02 - Terms of offer.docx
Document No. 03 - Framework Agreement and Terms and Conditions.docx
Document No. 04 - Quality Assurance Process.docx
Document No. 05 - Selectt offer schedule instructions.docx
Document No. 05a(i) - Tender Product Listing and Usage - CM_PHR_25_5731_01.xlsx
Document No. 05a(ii) - Selectt offer schedule - CM_PHR_25_5731_01.xml
Document No. 05b(i) - Tender Product Listing and Usage - CM_PHR_25_5731_02.xlsx
Document No. 05b(ii) - Selectt offer schedule - CM_PHR_25_5731_02.xml
Document No. 05c - Volume Discounts or Additional Products Offer Schedule - CM-PHR-25-5731.xls
Document No. 06 - Form of offer.docx
Document No. 07 - Quality control technical sheet.docx
Document No. 08 - Confidential information schedule.xlsx
Document No. 09 - Pharmacy Purchasing Points List - Participating Authorities (1).xlsx
Document No. 10 - FOR INFO ONLY - NOT FOR COMPLETION - PSQ Pass Fail Criteria (1).xlsx
Contracting authority
NHS England
- Public Procurement Organisation Number: PDPT-3135-BWWY
Wellington House, 133-135 Waterloo Rd
London
SE1 8UG
United Kingdom
Region: UKI45 - Lambeth
Organisation type: Public authority - central government